AR100625A1 - Formulación de ceritinib - Google Patents

Formulación de ceritinib

Info

Publication number
AR100625A1
AR100625A1 ARP150101661A ARP150101661A AR100625A1 AR 100625 A1 AR100625 A1 AR 100625A1 AR P150101661 A ARP150101661 A AR P150101661A AR P150101661 A ARP150101661 A AR P150101661A AR 100625 A1 AR100625 A1 AR 100625A1
Authority
AR
Argentina
Prior art keywords
ceritinib
tablet
pharmaceutical composition
binder
dose
Prior art date
Application number
ARP150101661A
Other languages
English (en)
Spanish (es)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53298568&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR100625(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of AR100625A1 publication Critical patent/AR100625A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1658—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2063—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cephalosporin Compounds (AREA)
ARP150101661A 2014-05-29 2015-05-27 Formulación de ceritinib AR100625A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462004359P 2014-05-29 2014-05-29

Publications (1)

Publication Number Publication Date
AR100625A1 true AR100625A1 (es) 2016-10-19

Family

ID=53298568

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP150101661A AR100625A1 (es) 2014-05-29 2015-05-27 Formulación de ceritinib

Country Status (27)

Country Link
US (4) US20170112834A1 (enExample)
EP (1) EP3148513B1 (enExample)
JP (3) JP6679578B2 (enExample)
KR (1) KR20170008239A (enExample)
CN (1) CN106456640B (enExample)
AR (1) AR100625A1 (enExample)
AU (3) AU2015265470A1 (enExample)
BR (1) BR112016027580A8 (enExample)
CA (1) CA2948291A1 (enExample)
CL (1) CL2016003047A1 (enExample)
DK (1) DK3148513T3 (enExample)
EA (1) EA036922B1 (enExample)
EC (1) ECSP16096826A (enExample)
ES (1) ES2792574T3 (enExample)
HU (1) HUE048950T2 (enExample)
IL (1) IL248835B (enExample)
MX (1) MX373624B (enExample)
PE (1) PE20170313A1 (enExample)
PH (1) PH12016502272A1 (enExample)
PL (1) PL3148513T3 (enExample)
PT (1) PT3148513T (enExample)
SG (1) SG11201609208UA (enExample)
SI (1) SI3148513T1 (enExample)
TN (1) TN2016000484A1 (enExample)
TW (1) TWI721946B (enExample)
UY (1) UY36140A (enExample)
WO (1) WO2015181739A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3148513T1 (sl) 2014-05-29 2020-07-31 Novartis Ag Formulacija ceritiniba
CN106176752B (zh) * 2015-05-07 2020-06-23 石药集团中奇制药技术（石家庄）有限公司 色瑞替尼药物组合物
CN109381440A (zh) * 2018-11-15 2019-02-26 威海贯标信息科技有限公司 一种艾乐替尼组合物
CN113244236B (zh) * 2021-06-01 2023-02-03 上海市第一人民医院 色瑞替尼在制备治疗甲状腺相关眼病的药物中的应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3632778A (en) * 1970-06-10 1972-01-04 Hoffmann La Roche Tablets containing l-dopa
MX2008011459A (es) 2006-03-06 2008-09-24 Wyeth Corp Formulaciones y procesos para tabletas.
US20080175901A1 (en) 2006-11-21 2008-07-24 Wyeth Pharmaceutical formulations of a crystal form of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol
US20090239920A1 (en) 2006-11-21 2009-09-24 Wyeth Pharmaceutical formulations of an anhydrate crystal form of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol
ME00811B (me) * 2006-12-08 2012-03-20 Novartis Ag JEDINJENJA l KOMPOZICIJE KAO INHIBITORI PROTEIN KINAZE
KR101364277B1 (ko) * 2006-12-08 2014-02-21 아이알엠 엘엘씨 단백질 키나제 억제제로서의 화합물
EP2090297A1 (en) 2008-02-13 2009-08-19 Boehringer Ingelheim International GmbH Formulations of flibanserin
WO2010025796A1 (en) 2008-09-04 2010-03-11 Cargill Incorporated Tabletting of ervthritol
JO3635B1 (ar) * 2009-05-18 2020-08-27 Millennium Pharm Inc مركبات صيدلانية صلبة وطرق لانتاجها
WO2011020526A1 (en) 2009-08-18 2011-02-24 Cargill, Incorporated Tabletting of erythritol and isomalt
CN106890147A (zh) * 2010-05-11 2017-06-27 田边三菱制药株式会社 含1‑(β‑D‑吡喃葡糖基)‑3‑(苯基噻吩基甲基)苯化合物的片剂
MX2013002326A (es) 2010-09-07 2013-03-18 Cargill Inc Mezcla solidificada de alcohol de azucar.
SI3148513T1 (sl) 2014-05-29 2020-07-31 Novartis Ag Formulacija ceritiniba

Also Published As

Publication number Publication date
JP2022078236A (ja) 2022-05-24
CN106456640A (zh) 2017-02-22
US20170112834A1 (en) 2017-04-27
ES2792574T3 (es) 2020-11-11
PE20170313A1 (es) 2017-04-18
TW201613580A (en) 2016-04-16
IL248835B (en) 2020-05-31
EA201692310A1 (ru) 2017-04-28
MX373624B (es) 2020-05-22
SI3148513T1 (sl) 2020-07-31
CA2948291A1 (en) 2015-12-03
US20190022095A1 (en) 2019-01-24
SG11201609208UA (en) 2016-12-29
PH12016502272A1 (en) 2017-02-06
JP7084955B2 (ja) 2022-06-15
AU2019232937B2 (en) 2020-10-15
US20200009141A1 (en) 2020-01-09
PT3148513T (pt) 2020-05-27
US11000523B2 (en) 2021-05-11
DK3148513T3 (da) 2020-05-25
JP2020114834A (ja) 2020-07-30
CN106456640B (zh) 2021-05-14
US12357630B2 (en) 2025-07-15
UY36140A (es) 2016-01-08
MX2016015736A (es) 2017-03-16
AU2019232937A1 (en) 2019-10-10
WO2015181739A1 (en) 2015-12-03
ECSP16096826A (es) 2018-04-30
JP6679578B2 (ja) 2020-04-15
EA036922B1 (ru) 2021-01-15
JP2017520619A (ja) 2017-07-27
IL248835A0 (en) 2017-01-31
CL2016003047A1 (es) 2017-04-07
AU2015265470A1 (en) 2016-11-24
EP3148513B1 (en) 2020-02-26
KR20170008239A (ko) 2017-01-23
AU2018203007B2 (en) 2019-07-18
TWI721946B (zh) 2021-03-21
BR112016027580A2 (pt) 2017-08-15
BR112016027580A8 (pt) 2021-06-29
US20210154194A1 (en) 2021-05-27
EP3148513A1 (en) 2017-04-05
PL3148513T3 (pl) 2020-08-24
TN2016000484A1 (en) 2018-04-04
AU2018203007A1 (en) 2018-05-17
HUE048950T2 (hu) 2020-09-28

Similar Documents

Publication Publication Date Title
NI201700169A (es) Derivados de sulfamoilarilamida ciclados y uso de los mismos como medicamentos para el tratamiento de la hepatitis b
ECSP19021223A (es) Derivado de glucagon, conjugado del mismo, composición que comprende el mismo y uso terapéutico del mismo
NI201600115A (es) Derivados de sulfamoilpirrolamida y su uso como medicamentos para el tratamiento de la hepatitis b.
MX2022006107A (es) Metodos y composiciones para dosificacion en terapia celular adoptiva.
CO2018004857A2 (es) Derivados de dihidroimidazopirazinona usados en el tratamiento del cáncer
CL2015002164A1 (es) Formulación combinada de dos compuesos antivirales.
UY35590A (es) Nuevos compuestos para el tratamiento del cáncer
CR20160006A (es) Derivados de pirrolamida sustituidos con glioxamida y su uso como medicamentos para el tratamiento de la hepatitis b
BR112016015838A8 (pt) compostos heterocíclicos aromáticos, composição farmacêutica compreendendo os referidos compostos e produto de combinação
MY196173A (en) Cot Modulators And Methods Of Use Thereof
EA201690102A1 (ru) Фармацевтическая композиция, содержащая диметилфумарат, для введения в низкой суточной дозе
MX2015008628A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
MX390570B (es) Composicion farmaceutica para la prevencion y/o tratamiento de dermatitis atopica que comprende antagonista de interleucina 31 (il-31) como ingrediente activo.
MX2016013245A (es) Regimen de dosificacion de liberacion inmediata de moduladores s1p.
MX389178B (es) Formulacion de proporcion fija de insulina glargina/lixisenatida.
AR095032A1 (es) Formulaciones de compuestos orgánicos, composición farmacéutica sólida comprimida por rodillo
AR100625A1 (es) Formulación de ceritinib
MX2015008032A (es) Una composicion farmaceutica que contiene candesartan cilexetilo y amlodipina.
ECSP16005208A (es) Composición farmacéutica anti-tuberculosis estable en una forma de un comprimido recubierto que comprende gránulos de isoniazid y gránulos de rifapentina y su proceso de preparación
MX2017013643A (es) Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde particulas y una matriz.
EP4631500A3 (en) STABLE MULTIPARTICULAR PHARMACEUTICAL COMPOSITION OF ROSUVASTATIN
PH12015501313A1 (en) Chloroprocaine-based pharmaceutical composition for repeated intrathecal administration
ECSP19024033A (es) Composiciones de tesofensina
UY35526A (es) Derivados de espiroindolina y composiciones farma céuticas de los mismos
BR112015022925A2 (pt) partículas de resina de fenilefrina e seu uso em formulações farmacêuticas

Legal Events

Date Code Title Description
FB Suspension of granting procedure